Some reports indicate the cannabis component is on its way to becoming the next rockstar cannabinoid of the legal weed movement.
There have been several reports over the past year or so suggesting that people all over the country who use hemp-derived cannabidiol (CBD) products are failing drug tests. This is apparently happening as the lack of FDA regulations has allowed cannabis companies to be inconsistent in their manufacturing process.
So, while these products are only supposed to contain no more than 0.3% THC (not enough to get you high or cause a failed drug screen), some have more. But a 2019 study suggests that CBD users really don’t have much to worry about when it comes to the possibility of failing a drug screen. However, if they are using another emerging, cannabis-derivative known as cannabinol (CBN), they might be putting themselves at risk.
Photo by pxfuel
Researchers at the University of Utah Health Science Center say that CBN users could have a difficult time passing a drug test. It seems that while examining a handful of cannabinoids to determine which of them, if any, might react with immunoassays — the most common type of drug test available — they found that CBN was more likely to cause a false positive for marijuana than other cannabinoids, such as CBD or cannabichromene (CBC) and cannabigerol (CBG).
Specifically, the study shows that the Beckman Coulter Emit II Plus Cannabinoid test can register a positive for pot with as little as 100 ng/ml CBN. Researchers say drug testing pros should keep this in mind.










